Safety of controlled-onset extended-release verapamil in middle-aged and older patients with hypertension and coronary artery disease

American Heart Journal

Volumn 142, Issue 6, 2001, Pages 1010-1015

  White, William B ^a   Johnson, Mary F ^b   Anders, Robert J ^c   Elliott, William J ^d   Black, Henry R ^d  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b PharmaNet Development Group Inc   (United States)

^c PFIZER INC   (United States)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; VERAPAMIL;

ADULT; AGE; AGED; ANGINA PECTORIS; ARTICLE; BACKACHE; BRADYCARDIA; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; ELDERLY CARE; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VERTIGO;

EID: 0035209775     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2001.119127     Document Type: Article

References (23)

1. How to improve adherence with prescribed treatment in hypertensive patients?
2. The impact of side effects on hypertension management: A Japanese survey
3. Variations in compliance among hypertensive patients by drug class: Implications for health care costs
4. Age and gender related changes in stereoselective pharmacokinetics and pharmacodynamics of verapamil and norverapamil
5. Antihypertensive therapy in the aged patient: Clinical pharmacokinetic considerations
6. Placebo-controlled evaluation of three doses of a controlled-onset, extended-release formulation of verapamil in the treatment of stable angina pectoris
7. Comparison of controlled-onset, extended-release verapamil with amlodipine and amlodipine plus atenolol on exercise performance and ambulatory ischemia in patients with chronic stable angina pectoris
8. Novel delivery system for verapamil designed to achieve maximal blood pressure control during the early morning
9. Nocturnal dosing of a novel delivery system of verapamil for systemic hypertension
10. Comparison of effects of controlled onset extended release verapamil at bedtime and nifedipine gastrointestinal therapeutic system on arising on early morning blood pressure, heart rate, and the heart rate-blood pressure product
11. Effects of the chronotherapeutic delivery of verapamil on circadian blood pressure in African American patients with hypertension
12. Chronotherapeutic delivery of verapamil in obese versus non-obese patients with essential hypertension
13. Gender and age effects on the ambulatory blood pressure and heart rate responses to antihypertensive therapy
14. Verapamil pharmacodynamics and disposition in young and elderly hypertensive patients: Altered electrocardiographic and hypotensive responses
15. Calcium antagonists in the elderly: A risk-benefit analysis
16. The impact of gender, age, and body mass index on the 24-hour efficacy of antihypertensive therapy
17. Aging alters verapamil elimination and dynamics: Single dose and steady-state responses
18. Comparative effects of three calcium antagonists, diltiazem, verapamil and nifedipine, on the sinoatrial and atrioventricular nodes: Experimental and clinical studies
19. Calcium antagonists: Mechanisms, therapeutic indications and reservations: A review
20. Continuation of initial antihypertensive medication after 1 year of therapy
21. Effect of initial drug choice on persistence with antihypertensive therapy: The importance of actual practice data
22. Observational studies of antihypertensive medication use and compliance: Is drug choice a factor in treatment adherence?
23. The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: Results from a population-based study in the elderly